Your Health, We Care
Vemurafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Limitation of Use: Vemurafenib is not indicated for treatment of patients with wild-type BRAF melanoma.
Vemurafenib is indicated for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
from FDA，2020.12
Scan code
Whatsapp
LuciusVersionofVemurafenib:DosageandAdministration,Indications,PrecautionsIndicationsVemurafenib is ···【more】
Recommended：572025-15-12
Vemurafenib can treat melanoma and Erdheim Chester Disease.【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：6
LuciusVersionofVemurafenib:DosageandAdministration,Indications,PrecautionsIndicationsVemurafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or ···【more】
Article source：Lucius LaosRelease date：2025-12-15Recommended：57
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
